IMS Capital Management Buys New Position in Zoetis Inc. $ZTS

Key Points

• IMS Capital Management has acquired a new position in Zoetis Inc. by purchasing 2,958 shares valued at approximately $461,000 in the second quarter.
• Zoetis reported a quarterly EPS of $1.76, surpassing estimates, with a revenue of $2.46 billion, reflecting a 4.2% increase year-over-year.
• Analysts have mixed opinions on Zoetis, with ratings ranging from "buy" to "hold," and a consensus target price of $200.88.

IMS Capital Management purchased a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,958 shares of the company's stock, valued at approximately $461,000.

Several other large investors have also modified their holdings of ZTS. Nova Wealth Management Inc. purchased a new stake in Zoetis in the 1st quarter valued at $25,000. 1248 Management LLC purchased a new stake in shares of Zoetis in the first quarter valued at about $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the first quarter worth about $29,000. Cornerstone Planning Group LLC boosted its stake in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after buying an additional 120 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 1.5%

Shares of ZTS stock opened at $142.43 on Wednesday. The business's fifty day moving average price is $150.82 and its 200 day moving average price is $156.17. The firm has a market capitalization of $63.12 billion, a PE ratio of 24.52, a P/E/G ratio of 2.32 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the previous year, the firm earned $1.56 EPS. The business's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on ZTS shares. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Argus restated a "buy" rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.